In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The CEO As R&D Chief – An Interview With Carl Zeiss’ Michael Kaschke

Executive Summary

Given the importance of rapid and persistence technology development in medical devices, why is it that so few medtech CEOs come from R&D? Michael Kaschke, president and CEO of Carl Zeiss, is the exception that proves the rule. Kaschke joined the company in 1992 and began a steady ascent through the management ranks. In an interview, adapted from a recent session in the Innovator’s Workbench series sponsored by the BioDesign Program at Stanford University, Kaschke talks about Zeiss and its strong R&D culture, about how his own background in technology development shapes his approach to decision-making and about the challenges the company has faced in the past and the ones it faces going forward.

You may also be interested in...

J&J’s New Path Forward – An Interview With Alex Gorsky

In his last interview before becoming CEO of Johnson & Johnson, Alex Gorsky talks about the changes that J&J has made recently in its medical device business and discusses his upcoming promotion to head of all of J&J.

Coty’s Newest CEO Spent 20 Years At L’Oreal Before Founding ‘New-Age’ Skin-Care Firm Orveda

Sue Nabi’s success at L’Oreal, where she headed the firm’s global L’Oreal Paris and Lancome businesses, her skin-care savvy as founder of the luxury, “clean, green and vegan” Orveda, and her experience as a career champion of diversity were major draws for Coty, where she begins as CEO on 1 September.

Showcasing Its Pandemic Response Drug Discovery, Berkeley Lights Prepares For IPO

Chief executive Eric Hobbs talks about the technology needed to accelerate antibody, cell therapy and synthetic biology, and prepare for the next pandemic.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts